{"product_id":"zyme-bcg-matrix","title":"(ZYME) Zymeworks Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Zymeworks Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. The page already shows a real preview of the actual deliverable, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZiihera 2024 FDA approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZiihera (zanidatamab) won U.S. FDA approval in 2024 for previously treated HER2-positive biliary tract cancer, making it Zymeworks Inc.'s first approved product family. The label gave Zymeworks a real revenue driver, not just pipeline value. By end-2025, Ziihera was Zymeworks Inc.'s clearest growth engine and the key reason it fits the \"Star\" slot in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHER2-positive BTC launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHER2-positive biliary tract cancer is a small market, but it is hard to treat and has little competition; in the US, BTC is only about 1-2 cases per 100,000 people each year. Zymeworks Inc. gained a first-mover edge with Ziihera, FDA-approved in November 2024 for previously treated HER2-positive BTC. Strong uptake can lift sales fast, so this launch fits the Star profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGEA late-stage expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZymeworks Inc.’s zanidatamab is in HER2-positive gastroesophageal adenocarcinoma, a far larger pool than biliary tract cancer; HER2 positivity is seen in about 10% to 20% of gastric\/GEJ tumors. The phase 2 data showed a 41% objective response rate, supporting late-stage upside. If phase 3 holds and approvals follow, this stays a growth-heavy Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBreast cancer expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHER2-positive breast cancer is a large, durable market: breast cancer caused about 670,000 deaths worldwide in 2022, and HER2-positive disease still represents roughly 15% to 20% of cases. Zymeworks’ zanidatamab adds a differentiated HER2-binding approach, so the program can still win share if it keeps showing strong efficacy and tolerability.\u003c\/p\u003e\n\u003cp\u003eThat makes the breast cancer expansion look like a Star in the BCG Matrix: a big market, clear unmet need, and room for better HER2 biology to matter. The key test is execution across late-stage data, label breadth, and uptake versus entrenched HER2 brands.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge HER2-positive demand base\u003c\/li\u003e\n\u003cli\u003eDifferentiation via dual HER2 binding\u003c\/li\u003e\n\u003cli\u003eHigh growth, high execution risk\u003c\/li\u003e\n\u003cli\u003eStar if data stay strong\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eColorectal cancer expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHER2-positive colorectal cancer is a strong Stars expansion for Zymeworks Inc.’s zanidatamab: colorectal cancer causes about 1.9 million new cases and 900,000 deaths a year, while HER2+ disease is only ~3%-5% of CRC, so the niche is still underused and bigger than BTC. That keeps the program in a high-growth zone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge CRC base\u003c\/li\u003e\n\u003cli\u003eLow HER2 penetration\u003c\/li\u003e\n\u003cli\u003eClear expansion upside\u003c\/li\u003e\n\u003cli\u003eFits Star profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZiihera: Zymeworks’ FDA-Approved Growth Star\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZiihera is Zymeworks Inc.'s clearest Star: FDA-approved in 2024, it moved from pipeline to revenue and can still scale in 2025-2026 across HER2-positive BTC, gastric\/GEJ, breast, and colorectal cancers. The mix of first-mover BTC sales and larger follow-on tumors keeps growth high while competition stays limited.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eWhy Star\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZiihera\u003c\/td\u003e\n\u003ctd\u003eApproved revenue driver\u003c\/td\u003e\n\u003ctd\u003eFDA 2024; BTC 1-2\/100,000; CRC HER2+ 3%-5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpansion\u003c\/td\u003e\n\u003ctd\u003eLarge upside\u003c\/td\u003e\n\u003ctd\u003eHER2+ gastric\/GEJ 10%-20%; breast 15%-20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eZymeworks’ BCG Matrix maps pipeline assets to guide invest, hold, or divest decisions amid biotech competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG snapshot of Zymeworks Inc. to ease portfolio prioritization and strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists trusted sources behind Zymeworks Inc. claims, helping investors verify assumptions fast and make better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJazz royalty stream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZymeworks licensed zanidatamab to Jazz, so sales of Ziihera can feed royalty income with little added selling cost. In 2025, that makes this stream the closest thing to a cash cow in Zymeworks Inc.'s BCG mix: high margin, low capital needs, and tied to an approved HER2 therapy. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone receipts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZymeworks Inc.’s zanidatamab deal can pay up to $325 million in development, regulatory, and commercial milestones, plus tiered royalties, so it can bring in cash without a big sales force. The U.S. FDA approved zanidatamab in November 2024 for previously treated HER2-positive biliary tract cancer, a clear trigger for milestone receipts. That cash can fund R\u0026amp;D and cut equity-dilution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMSD collaboration cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck Sharp \u0026amp; Dohme is one of Zymeworks’ key partnership cash streams, bringing research funding and milestone-based payments without heavy capital needs. In BCG terms, that makes it a Cash Cow: steady support, low spend, and repeatable pharma cash. That kind of income helps fund the pipeline while limiting dilution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLilly collaboration cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEli Lilly collaboration income gives Zymeworks Inc. a second cash engine beyond product development risk. Partnered discovery can bring upfront fees, research funding, and milestones, so the cash is steadier than pure pipeline bets. That makes it a true cash cow within the BCG view.\u003c\/p\u003e\n\u003cp\u003eIn 2025, Zymeworks reported collaboration revenue from partners, including Eli Lilly, as part of its non-dilutive funding mix. For a biotech with no large commercial product base, this kind of recurring partner cash matters because it helps fund R\u0026amp;D without leaning only on equity or debt.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExternal, non-dilutive funding\u003c\/li\u003e\n\u003cli\u003eUpfront, research, and milestone cash\u003c\/li\u003e\n\u003cli\u003eLower risk than internal pipeline alone\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-partner platform fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZymeworks Inc.'s multi-partner platform fees are a steady cash cow: alliances with Bristol-Myers Squibb, GSK, Daiichi Sankyo, Janssen, BeiGene, and Exelixis spread risk and bring in several small-to-mid inflows. In FY2025, these fees still mattered more as funding support than as the main growth driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6 major alliances\u003c\/li\u003e\n\u003cli\u003eRisk spread across partners\u003c\/li\u003e\n\u003cli\u003eSmall-to-mid recurring inflows\u003c\/li\u003e\n\u003cli\u003eFunds core R\u0026amp;D engine\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZanidatamab Is Zymeworks’ 2025 Cash Cow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZymeworks Inc.’s closest Cash Cow is zanidatamab royalty and milestone income: Jazz can pay up to $325 million in milestones, while Ziihera sales can add tiered royalties with low selling cost. The FDA approved Ziihera in November 2024 for previously treated HER2-positive biliary tract cancer, so 2025 cash inflow is tied to a live product.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003eKey 2025-2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eZanidatamab\u003c\/td\u003e\n\u003ctd\u003eUp to $325M milestones; royalty stream\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eZymeworks Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Zymeworks Inc. BCG Matrix report you’ll receive after purchase. No demo content or placeholders—just the same professionally formatted document. Once purchased, it’s ready to download, review, and use right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo second approved product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, Zymeworks Inc. had only one approved drug family, zanidatamab, so there was no second mature product to offset risk or build stable share. The rest of the pipeline was still in clinical or preclinical stages, which meant cash flow still depended on a single launch. In BCG terms, that is a clear Dog: low breadth, low market proof.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, Zymeworks stayed a clinical-stage biotech, so R\u0026amp;D still burned cash before durable sales arrived. That matters because clinical programs can eat tens of millions each year while revenue stays tied to milestones, not product demand. If assets fail to convert, the burn turns this Dog into a value trap.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy noncommercial assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy noncommercial assets in Zymeworks Inc. are classic Dogs: older internal programs with no clear approval path. They can absorb R\u0026amp;D cash and management time without generating meaningful revenue, so they drag returns. In a BCG view, Zymeworks Inc. should cut, out-license, or shut down these assets unless data show a real path to value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall internal sales base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZymeworks Inc. ended 2025 with a very narrow internal sales base: one clear lead asset, zanidatamab, drove the story while the rest of the pipeline stayed early stage. That makes weak programs easy Dogs, because there is no broad product mix to absorb a miss.\u003c\/p\u003e\n\u003cp\u003eThe setup is brittle: if the lead asset slows, there is little internal revenue depth to offset it. In BCG terms, any underperforming asset with low share and weak growth is likely to be classified as a Dog fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne lead asset dominated end-2025.\u003c\/li\u003e\n\u003cli\u003eNo diversified internal portfolio.\u003c\/li\u003e\n\u003cli\u003eWeak programs have little cushion.\u003c\/li\u003e\n\u003cli\u003eSmall misses turn into Dogs quickly.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHeavy SG\u0026amp;A versus revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZymeworks is a Dogs case because a launch still needs sales, compliance, and support costs even when revenue is thin. In FY2025, that kind of SG\u0026amp;A load can outgrow narrow product sales, turning the launch into a cash trap instead of a growth engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHeavy fixed SG\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eNarrow sales base\u003c\/li\u003e\n\u003cli\u003eCash burn risk\u003c\/li\u003e\n\u003cli\u003eLow scale leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZymeworks: One Drug Family, Dog Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZymeworks Inc. fits the Dogs label because FY2025 still relied on one approved drug family, zanidatamab, while the rest of the pipeline stayed early stage. That left little revenue depth and high burn risk. Weak legacy programs also look like Dogs because they can drain R\u0026amp;D without clear approval upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003cth\u003eBCG view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e1 approved drug family\u003c\/td\u003e\n\u003ctd\u003eDog risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarly-stage pipeline\u003c\/td\u003e\n\u003ctd\u003eLow share, low scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGEA market expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHER2-positive gastroesophageal adenocarcinoma is a far bigger pool than biliary tract cancer, with HER2 overexpression seen in about 15%-20% of gastric\/GEJ tumors. Zymeworks’ share was still small because zanidatamab was not yet a mature commercial franchise in this setting, so the base was thin. The upside was high, but in 2025-2026 the market outcome still depended on uptake, label breadth, and payer access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBreast market expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHER2-positive breast cancer is a huge target, with about 2.3 million new breast cancer cases a year globally and roughly 15%-20% being HER2-positive. Zanidatamab still has to win share against entrenched drugs like trastuzumab deruxtecan, so the segment stays a high-potential Question Mark for Zymeworks Inc. \u003c\/p\u003e\n\u003cp\u003eThat matters because even small adoption in this multi-billion-dollar oncology field could move revenue fast, but only if clinical data and launch uptake stay strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eColorectal market expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHER2-positive colorectal cancer is a small but fast-growing niche, with HER2 amplification in about 3% to 5% of colorectal cancers and global CRC incidence near 2.0 million cases a year in 2025. Zymeworks Inc. still had no approved share in this segment by end-2025, so the setup fits a Question Mark: low share now, but high upside if clinical data and uptake improve.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eZW49 HER2 ADC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZW49 remained a clinical-stage HER2-targeted antibody-drug conjugate through end-2025, with no FDA or EMA approval and no product revenue for Zymeworks Inc. in this asset. That keeps it in the Question Mark bucket: the science is real, but market share is still unproven and the readout risk is high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eEnd-2025: no approved market position\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eEarly-stage program, high trial risk\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePotential upside, but share is uncertain\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn BCG terms, ZW49 fits a high-growth, low-share slot, so it needs more data and capital before it can move toward a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEarly partnered bispecifics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZymeworks Inc.’s partnered bispecific work with LEO Pharma and Iconic Therapeutics stayed development-stage, so these programs fit the BCG Question Mark bucket. They could scale fast if data turns positive, but most early bispecifics never reach commercial leadership.\u003c\/p\u003e\n\u003cp\u003eThat’s the key risk: high upside, low certainty, and still little revenue proof.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 partnered bispecific tracks\u003c\/li\u003e\n\u003cli\u003eDevelopment-first, not commercial\u003c\/li\u003e\n\u003cli\u003eHigh upside, low hit rate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZymeworks’ High-Upside HER2 Bets Remain Question Marks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZymeworks Inc.’s Question Marks stayed low-share, high-upside bets in 2025-2026: HER2+ gastric\/GEJ is 15%-20% of tumors, HER2+ breast is about 2.3M cases a year with 15%-20% HER2+, and HER2+ colorectal is 3%-5% of CRC near 2.0M cases in 2025. ZW49 and partnered bispecifics were still development-stage, so revenue proof was thin.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025-2026 status\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHER2+ GI\u003c\/td\u003e\n\u003ctd\u003eHigh growth, low share\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZW49\u003c\/td\u003e\n\u003ctd\u003eNo approval\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBispecifics\u003c\/td\u003e\n\u003ctd\u003ePre-revenue\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235198968073,"sku":"zyme-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/zyme-bcg-matrix.webp?v=1785737030","url":"https:\/\/dcfanalyst.com\/products\/zyme-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}